Adjudication of Adverse Cardiovascular Events in Patients with Chronic Lymphocytic Leukaemia Treated with Ibrutinib: Deaths in GLOW or Blowing in the Wind?

View Full Paper

Ask AI

Bookmark

Authors

Discussion

This analysis reviews cardiovascular deaths associated with ibrutinib in the elderly CLL population, suggesting misattributions in the GLOW trial.

Deaths attributed to ibrutinib in the GLOW trial were misinterpreted, emphasizing the need for careful risk assessment.
The study highlights that hypertension and atrial fibrillation risks need to be weighed against treatment benefits in CLL.
Ibrutinib's cardiovascular effects reveal the importance of understanding the complex patient factors influencing outcomes.
GLOW trial findings should prompt clinicians to reassess the risk-benefit ratio of cancer therapies.

Esposito et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

This analysis reviews cardiovascular deaths associated with ibrutinib in the elderly CLL population, suggesting misattributions in the GLOW trial.